FPT-SOFTWARE
5.8.2024 09:31:33 CEST | Business Wire | Press release
Global technology company FPT Software, a subsidiary of FPT Corporation, and KITZ Corporation, a world-leading manufacturer of industrial valves and fluid control products, recently signed a strategic partnership agreement. The collaboration leverages FPT Software’s scalable workforce and robust expertise to accelerate the digital transformation initiatives across KITZ’s manufacturing and business operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240804936324/en/
The signing ceremony took place in Tokyo, Japan, with KITZ Corporation CEO Makoto Kohno, FPT Corporation EVP and FPT Software CEO Pham Minh Tuan, and senior executives from both sides. (Photo: Business Wire)
Under the agreement, FPT Software will provide digital solutions to enhance KITZ’s product development and design, global supply chain, maintenance services, and sales and marketing activities. FPT Software will also enhance KITZ’s IT infrastructure through cutting-edge, AI-infused solutions to facilitate its operation and manufacturing with greater precision, efficiency, and safety.
“Driving agility, scalability, and enhanced productivity for our clients has always been FPT Software’s priority. With two decades of experience accompanying industry giants in Japan, a diversified delivery network, and a high-quality workforce globally, we are confident to help KITZ streamline operations and improve time-to-market to stay ahead of the rapidly changing manufacturing landscape,” said Pham Minh Tuan, FPT Corporation Executive Vice President and FPT Software Chief Executive Officer.
"I believe that forming a strategic partnership with FPT, a company that provides the latest technologies and services in the digital field, is a significant step forward. We are currently constructing a factory in Vinh Phuc Province, Vietnam, to manufacture and sell stainless steel valves, which are expected to be in high demand in the future, and a factory to produce high-purity gas valves for the semiconductor equipment market. In Vietnam, which is experiencing remarkable growth, we will continue to provide products and services tailored to our customers' markets and regions by partnering with FPT, a global company that has been at the forefront of DX initiatives for many companies,” said Makoto Kohno, KITZ Corporation Chief Executive Officer.
With nearly 20 years in Japan, FPT Software has become one of the largest foreign technology firms in terms of workforce, with 3,500 employees across 17 local offices and innovation hubs, as well as 15,000 global employees dedicated to the Japanese market. The company has provided services and solutions to over 450 clients worldwide, supporting their digital transformation through strategic consulting services and advanced technological solutions such as AI, machine learning, and cloud computing. The IT firm also plays a significant role in promoting technology cooperation and development between Vietnam and Japan, notably an active member of the Japan Business Federation (Keidanren) and the chair of the Vietnam Association of Digital Transformation in Japan (VADX Japan).
Manufacturing is among FPT Software's key domains. It provides comprehensive strategies and execution processes for digital factories on a global scale, leveraging its deep expertise and wide skills network to deliver complex end-to-end projects that enhance manufacturing operations. These proven competencies and success place FPT Software as a leader and disruptor in manufacturing services by IDC MarketScape and HFS Horizons.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240804936324/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom